Pfizer Inc.’s general counsel will no longer oversee the company’s compliance program, under the terms of the company’s $2.3 billion settlement agreement resolving allegations that Pfizer’s executives and sales staff illegally marketed the painkiller Bextra and several other drugs.
Instead, the chief compliance officer at the world’s largest drug maker will report directly to the CEO. The move is required by Pfizer’s corporate integrity agreement with the office of the inspector general of the U.S. Department of Health and Human Services, which is part of the company’s civil and criminal settlement with the U.S. Department of Justice.
